Under the collaboration, BioSeek will apply its BioMAP Systems to support compound differentiation, lead development, and drug candidate selection activities for DSP’s discovery programs in the fields of inflammation and metabolic diseases.
Michael Venuti, CEO of BioSeek, said: “This collaboration leverages our technology platform’s power in addressing key decision points in the discovery process, making it extremely valuable to partners such as DSP.”